含有奥拉诺芬的PLGA纳米颗粒用于对抗引起的阿尔茨海默氏症的神经保护
Shiv Kumar Kushwaha1, Mahendra Singh Ashawat2, Rimpi Arora3
1Pharma Innovation Lab, Department of Pharmaceutical Sciences & Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, 151001, India.
Current pharmaceutical design
|January 21, 2025
概括
乌拉诺芬纳米颗粒有效地保护大鼠免受化诱导的阿尔茨海默病. 这些纳米粒子与单独的auranofin相比,显示出更好的神经保护,提供了一个有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 中枢神经系统 (CNS) 疾病的治疗方法有限,尤其是神经退行性疾病.
- 血脑屏障 (BBB) 限制了药物输送到大脑.
- 纳米配方增强了潜在的中枢神经系统疗法的BBB透率.
研究的目的:
- 探索使用 auranofin.fin. 的有效神经保护纳米配方.
- 评价用于阿尔茨海默病治疗的聚乳-同-甘油酸 (PLGA) 封装的奥拉诺芬纳米颗粒.
- 评估auranofin纳米颗粒对化诱导的神经退行症的疗效.
主要方法:
- 带有奥拉诺芬的PLGA纳米粒子被合成并以大小,电荷和捕获效率进行了表征.
- 小鼠接受化 (AlCl3) 诱导类似阿尔茨海默氏症的病理.
- 动物接受了auranofin或auranofin纳米颗粒的治疗,随后在海马中进行了生化和神经炎症标记分析.
主要成果:
- 奥拉诺芬纳米颗粒表现出高的捕获效率 (98%) 和负荷 (76%),平均尺寸为101.5nm.
- 口服奥拉诺芬纳米颗粒显著改善了AlCl3治疗的老鼠的认知缺陷.
- 治疗减少了神经炎症,并纠正了由AlCl3.3诱导的生化变化.
结论:
- 与单独的奥拉诺芬相比,奥拉诺芬纳米颗粒显示出更好的神经保护作用.
- 治疗效益与纳米颗粒的尺寸调节以及auranofin的抗氧化和抗炎性质有关.
- 金化合物纳米颗粒代表了阿尔茨海默病的有前途的治疗方法.
相关概念视频
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439


